Building scientific progress without borders: nanobiology and nanomedicine in China and the U.S.
Building scientific progress without borders: nanobiology and nanomedicine in China and the U.S.
复制标题
建设无国界的科学进步：中国和美国的纳米生物学和纳米医学
DOI：
10.1158/0008-5472.can-09-0563
复制
发表时间：
2009
期刊：
影响因子：
11.2
通讯作者：
Liang,Xing-Jie
中科院分区：
文献类型：
--
作者：
Wang,PaulC;Blumenthal,RobertP;Zhao,Yuliang;Schneider,JulieA;Miller,Nancy;Grodzinski,Piotr;Gottesman,MichaelM;Tinkle,Sally;Wang,Kuan;Wang,Chen;Liang,Xing-Jie
In recent years, growing numbers of nanomaterials and nanotechnology applications have been used as novel imaging, diagnostic, and therapeutic agents in the treatment of cancer and other diseases. The safe and effective development and use of these new nanotechnologies will require coordinated effort among diverse groups of international experts including basic scientists, toxicologists, clinical researchers, policymakers, and others. The first Joint China-US Symposium on Nanobiotechnology and Nanomedicine was convened October 21 to 23, 2008, in Beijing, China, to address these and other emerging issues and opportunities (Supplementary Fig. S1). The goal of the symposium was to share experiences and exchange information pertaining to the development of nanotechnology for medical use including the prevention, detection, and treatment of disease, and ensuring the safety of the general public and of personnel working in the field. The symposium also provided a platform for exploring the development of new research collaborations among top Chinese and American scientists.This symposium was organized in response to recent major investments in nanobiology and nanomedicine both in China and in the United States, respectively. Discussions focused on nanotechnology applications for cancer diagnostics and therapeutics, given the substantial advances in this field. The organization of the meeting was collaboratively developed by the National Center for Nanoscience and Technology of China, a leading nanotechnology research institution, and by the Chinese Academy of Sciences and Ministry of Science and Technology of China, as well as by the National Cancer Institute of the NIH and its Alliance for Nanotechnology in Cancer, and by the NIH’s National Institute of Environmental Health Sciences. Additional key supporters included the NIH Office of the Director, and the Trans-NIH Nanotechnology Task Force. The meeting was initiated under the auspices of an agreement cosigned by Executive President, Dr. Chunli Bai
